Riverview Trust Co Sells 538 Shares of CVS Health Corporation $CVS

Riverview Trust Co lessened its holdings in CVS Health Corporation (NYSE:CVS) by 56.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 418 shares of the pharmacy operator’s stock after selling 538 shares during the quarter. Riverview Trust Co’s holdings in CVS Health were worth $29,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Bell Investment Advisors Inc increased its stake in shares of CVS Health by 119.8% in the first quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator’s stock valued at $31,000 after buying an additional 248 shares during the period. Roxbury Financial LLC raised its position in shares of CVS Health by 78.3% in the 2nd quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator’s stock worth $32,000 after acquiring an additional 202 shares in the last quarter. ORG Partners LLC lifted its stake in shares of CVS Health by 418.9% in the 2nd quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator’s stock valued at $32,000 after purchasing an additional 377 shares during the period. Saudi Central Bank bought a new stake in shares of CVS Health during the 1st quarter valued at about $34,000. Finally, Livelsberger Financial Advisory bought a new stake in CVS Health in the second quarter worth approximately $35,000. 80.66% of the stock is owned by institutional investors.

CVS Health Trading Up 1.9%

NYSE CVS opened at $76.84 on Thursday. The stock has a market capitalization of $97.46 billion, a price-to-earnings ratio of 21.46, a PEG ratio of 0.83 and a beta of 0.60. CVS Health Corporation has a one year low of $43.56 and a one year high of $77.54. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.80 and a quick ratio of 0.62. The business’s fifty day moving average is $70.00 and its 200-day moving average is $67.19.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The business had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. During the same quarter last year, the company posted $1.83 earnings per share. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Thursday, October 23rd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.5%. CVS Health’s dividend payout ratio (DPR) is 74.30%.

Insiders Place Their Bets

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares in the company, valued at $1,573,519.12. This trade represents a 25.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CVS. Robert W. Baird upgraded shares of CVS Health from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $71.00 to $82.00 in a research note on Thursday, August 14th. Zacks Research lowered CVS Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 8th. Barclays lifted their price objective on shares of CVS Health from $80.00 to $87.00 and gave the company an “overweight” rating in a report on Thursday, September 4th. Bernstein Bank dropped their price target on shares of CVS Health from $78.00 to $72.00 and set a “market perform” rating on the stock in a research report on Wednesday, July 16th. Finally, Wolfe Research increased their price objective on CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $78.25.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.